Asklepion Pharmaceuticals Signs Contract to Utilize NetraMark Technology in Phase III Pediatric Cardiac Study
NetraMark Holdings (OTCQB: AINMF) has signed a contract with Asklepion Pharmaceuticals to deploy its NetraAI platform for analyzing results from a pivotal Phase III pediatric clinical trial. The study, CIT-003-01, evaluates the efficacy of intravenous L-citrulline in preventing acute lung injury in children undergoing cardiopulmonary bypass surgery for congenital heart defects.
NetraAI's technology will utilize explainable AI and generative modeling to optimize trial outcomes through enhanced patient stratification and identification of responder personas. The partnership aims to demonstrate L-citrulline's benefits in specific patient subgroups and inform future study designs.
NetraMark Holdings (OTCQB: AINMF) ha firmato un contratto con Asklepion Pharmaceuticals per implementare la sua piattaforma NetraAI nell'analisi dei risultati di uno studio clinico pediatrico di Fase III fondamentale. Lo studio, CIT-003-01, valuta l'efficacia della L-citrullina somministrata per via endovenosa nella prevenzione del danno polmonare acuto nei bambini sottoposti a bypass cardiopolmonare per difetti cardiaci congeniti.
La tecnologia NetraAI utilizzerà l'intelligenza artificiale spiegabile e la modellazione generativa per ottimizzare i risultati dello studio attraverso una migliore stratificazione dei pazienti e l'identificazione dei profili di risposta. La collaborazione mira a dimostrare i benefici della L-citrullina in specifici sottogruppi di pazienti e a guidare la progettazione di studi futuri.
NetraMark Holdings (OTCQB: AINMF) ha firmado un contrato con Asklepion Pharmaceuticals para implementar su plataforma NetraAI en el análisis de los resultados de un ensayo clínico pediátrico pivotal de Fase III. El estudio, CIT-003-01, evalúa la eficacia de la L-citrulina intravenosa para prevenir lesiones pulmonares agudas en niños sometidos a cirugía de bypass cardiopulmonar por defectos congénitos del corazón.
La tecnología NetraAI utilizará inteligencia artificial explicable y modelado generativo para optimizar los resultados del ensayo mediante una mejor estratificación de los pacientes e identificación de perfiles de respondedores. La colaboración busca demostrar los beneficios de la L-citrulina en subgrupos específicos de pacientes y orientar el diseño de futuros estudios.
NetraMark Holdings (OTCQB: AINMF)는 Asklepion Pharmaceuticals와 계약을 체결하여 중대한 3상 소아 임상시험 결과 분석을 위해 NetraAI 플랫폼을 도입합니다. CIT-003-01 연구는 선천성 심장 결함으로 심폐 우회 수술을 받는 어린이들의 급성 폐 손상 예방을 위한 정맥 주사용 L-시트룰린의 효능을 평가합니다.
NetraAI 기술은 설명 가능한 인공지능과 생성 모델링을 활용하여 환자 계층화 및 반응자 유형 식별을 통해 시험 결과를 최적화합니다. 이 파트너십은 특정 환자 하위 그룹에서 L-시트룰린의 이점을 입증하고 향후 연구 설계에 정보를 제공하는 것을 목표로 합니다.
NetraMark Holdings (OTCQB : AINMF) a signé un contrat avec Asklepion Pharmaceuticals pour déployer sa plateforme NetraAI afin d'analyser les résultats d'un essai clinique pédiatrique de phase III crucial. L'étude CIT-003-01 évalue l'efficacité de la L-citrulline administrée par voie intraveineuse pour prévenir les lésions pulmonaires aiguës chez les enfants subissant une chirurgie de dérivation cardiopulmonaire pour des malformations cardiaques congénitales.
La technologie NetraAI utilisera l'intelligence artificielle explicable et la modélisation générative pour optimiser les résultats de l'essai grâce à une meilleure stratification des patients et à l'identification des profils de répondeurs. Ce partenariat vise à démontrer les bénéfices de la L-citrulline dans des sous-groupes spécifiques de patients et à orienter la conception des études futures.
NetraMark Holdings (OTCQB: AINMF) hat einen Vertrag mit Asklepion Pharmaceuticals unterzeichnet, um seine NetraAI-Plattform für die Analyse der Ergebnisse einer entscheidenden Phase-III-Pädiatrie-Studie einzusetzen. Die Studie CIT-003-01 bewertet die Wirksamkeit von intravenösem L-Citrullin zur Vorbeugung von akutem Lungenschaden bei Kindern, die sich einer kardiopulmonalen Bypass-Operation wegen angeborener Herzfehler unterziehen.
Die Technologie von NetraAI wird erklärbare KI und generatives Modellieren nutzen, um die Studienergebnisse durch verbesserte Patientensegmentierung und Identifikation von Ansprechertypen zu optimieren. Die Partnerschaft zielt darauf ab, die Vorteile von L-Citrullin in bestimmten Patientengruppen nachzuweisen und zukünftige Studiendesigns zu informieren.
- Partnership with Asklepion validates NetraMark's AI technology in late-phase clinical trials
- Application in pediatric clinical trials demonstrates versatility of NetraAI platform
- Focus on responder personas could improve future trial designs and patient outcomes
- No financial terms or contract value disclosed
- Timeline for analysis completion and results not specified
TORONTO, Aug. 05, 2025 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0) a premier artificial intelligence (AI) company transforming clinical trials today announced it has signed a contract with Asklepion Pharmaceuticals to deploy its NetraAI platform to analyze results from its pivotal Phase III pediatric clinical trial.
The agreement covers the application of NetraAI’s advanced AI technology to analyze patient data from Asklepion’s CIT-003-01 study, which evaluated the efficacy of intravenous L-citrulline for preventing acute lung injury in children undergoing cardiopulmonary bypass surgery for congenital heart defects.
Asklepion is deeply focused on translating science into meaningful therapies for children. By incorporating NetraMark’s AI analytics into their trial framework, they aim to enhance their ability to demonstrate the benefits of L-citrulline in specific patient subgroups. This approach reflects Asklepion’s ongoing pursuit of excellence in both science and strategy. By leveraging explainable AI and generative modeling, NetraAI seeks to enable precision trial optimization by delivering actionable insights that can enhance patient stratification and improve study outcomes.
“Asklepion’s decision to engage NetraMark reflects a forward-thinking commitment to innovation in trial design,” said Josh Spiegel, President of NetraMark. “We are proud to bring our AI-driven capabilities to a program with such clinical importance and look forward to delivering insights that can optimize patient selection and study outcomes.”
“We are committed to pushing the boundaries of pediatric drug development, and NetraMark’s technology offers a compelling path forward,” said Mr. Jeff Courtney, Chief Executive Officer at Asklepion Pharmaceuticals. “By integrating NetraAI’s explainable AI based analytics into our late phase study, we hope to uncover meaningful insights that sharpen our understanding of L-citrulline,” as stated by Dr. Gurdyal Kalsi, Chief Medical Officer at Asklepion Pharmaceuticals. “This partnership underscores our belief in the power of innovation to accelerate safer, more effective treatments for children.”
NetraMark’s analysis will focus on identifying responder personas—subpopulations of patients who are most likely to benefit from treatment. These insights will inform study designs for future L-citrulline development.
About NetraMark
NetraMark is a company focused on being a leader in the development of Generative Artificial Intelligence (Gen AI)/Machine Learning (ML) solutions targeted at the Pharmaceutical industry. Its product offering uses a novel topology-based algorithm that has the ability to parse patient data sets into subsets of people that are strongly related according to several variables simultaneously. This allows NetraMark to use a variety of ML methods, depending on the character and size of the data, to transform the data into powerfully intelligent data that activates traditional AI/ML methods. The result is that NetraMark can work with much smaller datasets and accurately segment diseases into different types, as well as accurately classify patients for sensitivity to drugs and/or efficacy of treatment.
For further details on the Company please see the Company’s publicly available documents filed on the System for Electronic Document Analysis and Retrieval+ (SEDAR+).
For more NetraMark information, see the company’s website and follow NetraMark on LinkedIn.
Forward-Looking Statements
This press release contains "forward-looking information" within the meaning of applicable Canadian securities legislation including statements regarding the capabilities of Netra AI to deliver actionable insights to enhance patient stratification and improve study outcomes, the ability of Netra AI to uncover meaningful insights for Asklepion that sharpen understanding of L-citrulline and inform study designs for future L-citrulline development which are based upon NetraMark’s current internal expectations, estimates, projections, assumptions and beliefs, and views of future events. Forward-looking information can be identified by the use of forward-looking terminology such as “expect”, “likely”, “may”, “will”, “should”, “intend”, “anticipate”, “potential”, “proposed”, “estimate” and other similar words, including negative and grammatical variations thereof, or statements that certain events or conditions “may”, “would” or “will” happen, or by discussions of strategy. Forward-looking information includes estimates, plans, expectations, opinions, forecasts, projections, targets, guidance, or other statements that are not statements of fact. The forward-looking statements are expectations only and are subject to known and unknown risks, uncertainties and other important factors that could cause actual results of the Company or industry results to differ materially from future results, performance or achievements. Any forward-looking information speaks only as of the date on which it is made, and, except as required by law, NetraMark does not undertake any obligation to update or revise any forward-looking information, whether as a result of new information, future events, or otherwise. New factors emerge from time to time, and it is not possible for NetraMark to predict all such factors.
When considering these forward-looking statements, readers should keep in mind the risk factors and other cautionary statements as set out in the materials we file with applicable Canadian securities regulatory authorities on SEDAR+ at www.sedarplus.ca including our Management’s Discussion and Analysis for the year ended September 30, 2024. These risk factors and other factors could cause actual events or results to differ materially from those described in any forward-looking information.
The CSE does not accept responsibility for the adequacy or accuracy of this release.
Contact Information:
Swapan Kakumanu - CFO | swapan@netramark.com | 403-681-2549
FAQ
What is the purpose of Asklepion's Phase III clinical trial that will use NetraMark's AI technology?
How will NetraMark's AI technology benefit Asklepion's clinical trial?
Who are the key executives involved in the NetraMark (AINMF) and Asklepion partnership?
What is the significance of this partnership for NetraMark (AINMF)?
